Valneva says the EMA wants additional data about its experimental COVID-19 shot
U.S.-listed shares of Valneva SE tumbled 14.4% in premarket trading on Monday after the company said the European Medicines Agency had requested additional information about its COVID-19 vaccine candidate. Valneva said it will respond to the request, and if the new data are accepted by the EMA's Committee for Medicinal Products for Human Use, it expects authorization this quarter. The U.K. recently authorized Valneva's COVID-19 shot. Valneva's stock has declined 50.1% this year, while the broader S&P 500 is down 10.3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.